Clark D J, Clark R A, Lipworth B J
Department of Clinical Pharmacology, University of Dundee, UK.
Thorax. 1996 Sep;51(9):941-3. doi: 10.1136/thx.51.9.941.
The aim of this study was to compare the systemic bioactivity of inhaled budesonide (B) and fluticasone propionate (F), each given by large volume spacer, on a microgram equivalent basis in asthmatic children.
Ten stable asthmatic children of mean age 11 years and forced expiratory volume in one second (FEV1) 81.6% predicted, who were receiving treatment with < or = 400 micrograms/day of inhaled corticosteroid, were studied in a placebo controlled single blind (investigator blind) randomised crossover design comparing single doses of inhaled budesonide and fluticasone propionate 400 micrograms, 800 micrograms, and 1250 micrograms. Doses were given at 20.00 hours with mouth rinsing and an overnight 12 hour urine sample was collected for estimation of free cortisol and creatinine excretion.
The results of overnight 12 hour urinary cortisol output (nmol/12 hours) showed suppression with all doses of fluticasone propionate (as geometric means): F400 micrograms (11.99), F800 micrograms (6.49), F1250 micrograms (7.00) compared with placebo (24.43), whereas budesonide caused no suppression at any dose. A comparison of the drugs showed that there were differences at 800 micrograms and 1250 micrograms levels for urinary cortisol: B800 micrograms versus F800 micrograms (2.65-fold, 95% CI 1.26 to 5.58), B1250 micrograms versus F1250 micrograms (2.94-fold, 95% CI 1.67 to 5.15). The results for the cortisol/creatinine ratio were similar to that of urinary cortisol, with fluticasone causing suppression at all doses and with differences between the drugs at 800 micrograms and 1250 micrograms.
Single doses of inhaled fluticasone produce greater systemic bioactivity than budesonide when given by large volume spacer on a microgram equivalent basis in asthmatic children. The systemic bioactivity of fluticasone, like budesonide, is due mainly to lung bioavailability.
本研究旨在比较通过大容量储雾罐给予哮喘儿童的吸入用布地奈德(B)和丙酸氟替卡松(F)在微克等效剂量基础上的全身生物活性。
对10名平均年龄11岁、一秒用力呼气容积(FEV1)为预测值81.6%、正在接受每日吸入糖皮质激素剂量≤400微克治疗的稳定期哮喘儿童,采用安慰剂对照、单盲(研究者盲法)随机交叉设计,比较单剂量吸入布地奈德和丙酸氟替卡松400微克、800微克和1250微克的效果。剂量于20:00给予,给药后漱口,并收集过夜12小时尿液样本以测定游离皮质醇和肌酐排泄量。
过夜12小时尿皮质醇排出量(纳摩尔/12小时)结果显示,所有剂量的丙酸氟替卡松均有抑制作用(几何均值):F400微克(11.99)、F800微克(6.49)、F1250微克(7.00),与安慰剂(24.43)相比,而布地奈德在任何剂量下均未引起抑制。药物比较显示,在800微克和1250微克剂量水平时尿皮质醇有差异:B800微克与F800微克相比(2.65倍,95%可信区间1.26至5.58),B1250微克与F1250微克相比(2.94倍,95%可信区间1.67至5.15)。皮质醇/肌酐比值结果与尿皮质醇相似,丙酸氟替卡松在所有剂量下均有抑制作用,且在800微克和1250微克时药物之间存在差异。
在哮喘儿童中,以微克等效剂量通过大容量储雾罐给药时,单剂量吸入丙酸氟替卡松比布地奈德产生更大的全身生物活性。与布地奈德一样,丙酸氟替卡松的全身生物活性主要归因于肺部生物利用度。